Taysha Gene Therapies (TSHA) risk factors, FY2025 10-K

Other

1. 01Selected Risks Affecting Our Business
2. 02We have a limited operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability
3. 03We intend to identify and develop novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development24% rewritten
4. 04Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business100% rewritten
5. 05UT Southwestern has entered into collaborations with third parties, including certain of our competitors, addressing targets and disease indications outside the scope of our collaboration. As a result, UT Southwestern may have competing interests with respect to their priorities and resources
6. 06We may be subject to legal proceedings from time to time which seek material damages

Risks Related to our Financial Position and Capital Needs

1. 07We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability21% rewritten
2. 08incur additional legal, accounting and other expenses in operating as a public company
3. 09We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to develop commercial capabilities, and we may not be successful in doing so
4. 10the costs of operating as a public company
5. 11Our existing indebtedness contains restrictions that potentially limit our flexibility in operating our business. In addition, we may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect under our 2025 Trinity Term Loan Agreement if we are unable to satisfy certain conditions33% rewritten
6. 12enter into material transactions with affiliates24% rewritten
7. 13At closing, we drew $50.0 million
8. 14Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
9. 15Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations

Risks Related to the Development of our Product Candidates

1. 16TSHA-102 is currently our lead product candidate and there is no guarantee that we will be able to successfully develop and commercialize TSHA-102
2. 17maintaining a continued acceptable safety, tolerability and efficacy profile of the products following approval
3. 18Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop
4. 19Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates46% rewritten
5. 20manufacturing sufficient quantities of product candidate for use in clinical trials
6. 21any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us
7. 22have the product removed from the market after obtaining marketing approval
8. 23The regulatory approval processes of the FDA, European Commission and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed70% rewritten
9. 24foreign authorities, regarding clinical development programs or regulatory approval for any product candidate outside of the United StatesNew
10. 25Interim “top-line” and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data79% rewritten
11. 26actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize any of our product candidates, our business, operating results, prospects or financial condition may be harmedNew
12. 27We have not yet completed testing of any product candidate in clinical trials. Success in preclinical studies or earlier clinical trials, including our Phase 1/2 REVEAL trials of TSHA-102, may not be indicative of results in future clinical trials, or provide support for the submission of a marketing application78% rewritten
13. 28our reputation and physician or patient acceptance of our products may suffer
14. 29As an organization, we have not previously conducted pivotal clinical trials such as REVEAL Part BNew
15. 30The disorders we seek to treat have low prevalence and it may be difficult to identify and enroll patients with these disorders. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
16. 31the proximity and availability of clinical trial sites for prospective patients
17. 32We may seek orphan drug designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity, for product candidates for which we obtain orphan drug designation
18. 33We have received rare pediatric disease designation for TSHA-102 for the treatment of Rett syndrome. However, a marketing application for TSHA-102, if approved, may not meet the eligibility criteria for a PRV or the rare pediatric disease designation program may sunset before FDA is able to consider us for a voucher
19. 34the BLA is approved for a different adult indication than the rare pediatric disease for which TSHA-102 is designated29% rewritten
20. 35We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success73% rewritten
21. 36We are currently conducting our TSHA-102 REVEAL trials in Canada and plan to conduct in the future additional clinical trials for our product candidates outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trialsNew
22. 37We may not be successful in our efforts to build a pipeline of additional product candidates
23. 38If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed29% rewritten

Risks Related to the Manufacturing of our Product Candidates

1. 39Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business100% rewritten
2. 40The manufacture of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies
3. 41We and our contract manufacturers for AAV9 are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely may have limited capacity or fail to meet the applicable stringent regulatory requirements
4. 42studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelinesNew
5. 43We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business
6. 44Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers of plasmids and viruses to deliver necessary components could result in delays in our clinical development or marketing schedules
7. 45Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay

Risks Related to the Commercialization of our Product Candidates

1. 46Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 47Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or commercial success of our current and future product candidates
3. 48If we are unable to establish sales, marketing and distribution capabilities for TSHA-102 or any other product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved48% rewritten
4. 49any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnelNew
5. 50unforeseen costs and expenses associated with creating an independent sales and marketing organization
6. 51The affected populations for our other product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates
7. 52We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively
8. 53successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines
9. 54Biologic products may face competition sooner than anticipated
10. 55The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these procedures30% rewritten
11. 56of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member StatesNew
12. 57Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
13. 58the inability to commercialize any products that we may develop

Risks Related to Our Dependence on Third Parties

1. 59We intend to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials
2. 60We may seek collaborations with third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates
3. 61collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates

Risks Related to our Intellectual Property

1. 62If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market
2. 63If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, we could lose rights that are important to our business
3. 64Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents
4. 65We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful
5. 66We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our product candidates
6. 67Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
7. 68We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
8. 69We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property
9. 70Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
10. 71We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
11. 72Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
12. 73Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business
13. 74Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Legal and Regulatory Compliance Matters

1. 75resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our businessNew
2. 76Even if we obtain regulatory approval for TSHA-102 or any future product candidates, they will remain subject to ongoing regulatory oversight77% rewritten
3. 77refuse to allow us to enter into supply contracts, including government contracts
4. 78In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy
5. 79Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations75% rewritten
6. 80additional recordkeeping91% rewritten

Risks Related to Employee Matters and Managing our Growth

1. 81Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel, and recent changes to our team might harm future operating results45% rewritten
2. 82Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements

Risks Related to Ownership of our Common Stock

1. 83The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses
2. 84other events or factors, many of which are beyond our control
3. 85If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
4. 86Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
5. 87An active trading market for our common stock may not be sustained96% rewritten
6. 88Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
7. 89stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings
8. 90Concentration of ownership of our common stock among our principal stockholders may prevent new investors from influencing significant corporate decisions74% rewritten
9. 91requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactionsNew
10. 92Because we are no longer an "emerging growth company" as defined in the JOBS Act, we may incur additional expenses and devote increased management time to compliance with additional disclosures that are applicable to companies that are not emerging growth companiesNew
11. 93We have broad discretion in the use our cash and cash equivalents
12. 94Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment
13. 95any action asserting a claim against us that is governed by the internal-affairs doctrine

General Risks

1. 96diversions, diversion of management attention, interruptions in our operations, financial loss, additional reporting requirements and/or oversight, and restrictions on Processing sensitive information (including personal data)New
2. 97security measures that we (and our third parties) have integrated into our platform, systems, networks and physical facilities, which are designed to protect against, detect and minimize security breaches, may not be adequate to prevent or detect service interruption, system failure or data lossNew
3. 98Our business activities will be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws
4. 99We are obligated to maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock24% rewritten
5. 100Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
6. 101We might not be able to utilize a significant portion of our net operating loss carryforwards24% rewritten
7. 102New tax laws or regulations, changes to existing tax laws or regulations or changes in their application to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations52% rewritten
8. 103We have incurred and will continue to incur increased costs and demands upon management as a result of being a public company44% rewritten
9. 104activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmedNew